文献速递免疫规划妇幼与学校卫生

孕期流感疫苗接种后体质指数与疫苗应答的关系

Body mass index and vaccine responses following influenza vaccination during pregnancy.
PubMed 文献 · Vaccine · 2021-07-12

本研究纳入2014-2016年南澳大利亚96名孕妇,于接种季节性流感疫苗前及接种后一个月采血检测血凝抑制抗体。结果显示高BMI并未损害疫苗血清保护水平,但接种时的孕周可能影响保护效果,尤其早孕期接种者的血清保护比例较低。

要点

  • 高BMI孕妇接种流感疫苗后未出现血清保护水平受损。
  • 第二或第三孕期接种者血清保护比例高于第一孕期接种者。
  • 第一孕期流感疫苗应答值得进一步评估。

核心结论

  • 高BMI并未损害孕妇接种流感疫苗后的血清保护水平。
  • 接种时孕周可能是优化孕妇及新生儿疫苗保护的重要考虑因素。
  • 有必要进一步评估第一孕期流感疫苗应答。

研究设计与样本

  • 前瞻性观察研究,纳入2014-2016年南澳大利亚妇女儿童医院孕妇96名,中位孕周22周,BMI范围18-49 kg/m2。
  • 接种前及接种后一个月采血,以血凝抑制试验检测抗体应答。
  • 配对血清样本可获取率为90/96(94%)。

主要发现

  • 72/90(80%)孕妇接种后对三种流感疫苗抗原均达到血清保护抗体滴度。
  • 与BMI<30 kg/m2者相比,高BMI者未达到血清保护抗体的可能性更低,但差异无统计学意义(RR 0.42,95%CI 0.11-1.68;p=0.22)。
  • 第二孕期接种者47/53(93%)、第三孕期接种者18/25(72%)对三种抗原均达血清保护,第一孕期接种者为7/12(58%)。

关键数值与推荐

  • 血清保护定义为接种后血凝抑制抗体滴度≥1:40。
  • 检测的疫苗抗原文为A(H1N1)pdm09、A(H3N2)和B/Yamagata。

临床怎么用

  • 孕期接种流感疫苗时可将孕周作为优化保护的考虑因素。
  • 高BMI不应成为孕期流感疫苗接种的顾虑因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Influenza vaccination is recommended by the World Health Organisation for pregnant women, offering the dual benefit of protecting pregnant women and their newborn infants against influenza infection. Various factors can influence vaccine immunogenicity, with obesity being one factor implicated in varied responses. This study aimed to investigate the impact of body mass index (BMI) on vaccine responses following influenza vaccination during pregnancy. METHODS: Pregnant women attending the Women's and Children's Hospital in South Australia during 2014-2016 were invited to participate. Participant's clinical and demographic factors were recorded prior to administration of licensed seasonal influenza vaccination. Blood samples were collected before and one month post-vaccination to measure antibody responses by haemagglutination inhibition (HI) assay. Seroprotection was defined as a post-vaccination HI titre ≥ 1:40. Regression models assessed associations with failure to achieve seroprotective antibodies to H1, H3, and B influenza strains. RESULTS: A total of 96 women were enrolled in the study at a median gestation of 22 weeks with a BMI range of 18-49 kg/m2. Paired sera samples were available for 90/96 (94%). Most pregnant women (72/90, 80%) demonstrated seroprotective antibody titres to all three influenza vaccine antigens (A(H1N1)pdm09, A(H3N2), B/Yamagata) following vaccination. Compared with women with BMI < 30 kg/m2, those with high BMI were less likely to fail to achieve seroprotective antibodies, however this was not statistically significant (RR 0.42, 95% CI 0.11-1.68; p = 0.22). A greater proportion of women vaccinated during their second (47/53, 93%) or third trimester (18/25, 72%) demonstrated seroprotection to all three vaccine antigens following vaccination compared with women vaccinated during their first trimester (7/12, 58%). CONCLUSION: High BMI did not impair seroprotection levels following influenza vaccination in pregnant women. Gestation at vaccination may be an important consideration for optimising vaccine protection for pregnant women and their newborns. Further assessment of first trimester influenza vaccine responses is warranted.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Clarke M, Goodchild LM, Evans S, et al. Body mass index and vaccine responses following influenza vaccination during pregnancy. Vaccine. 2021. PMID: 34266699. doi:10.1016/j.vaccine.2021.06.065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。